Ryan Lamers, a CIHR and CFC-funded postdoctoral fellow in the Burrows lab, reviewed the state of drug development for the major opportunistic pathogen, Pseudomonas aeruginosa, especially as related to cell wall, in a paper published online today in Future Medicinal Chemistry. The bacterial cell wall has historically been a key target for antibiotics, but only a small fraction of the proteins involved in its biosynthesis and maintenance have been exploited so far. This review provides an overview of other potential targets and the stage of discovery for agents against these alternate targets.